Publication AWA
At the Public Information Bulletin of the Agency for Health Technology Assessment and Tariff System (AWA) has published reviews analyses for the evaluation of reimbursement applications
- Altuvoct (efanesoctocog alfa) in preventing bleeding in children with hemophilia A and B
- Staloral 300 for allergic conditions
- Phesgo (pertuzumab, trastuzumab) w leczeniu chorych na raka piersi
- Blincyto (blinatumomab) in the treatment of patients with acute lymphoblastic leukemia
- Pluvicto (lutetium (177Lu) vipivotide tetraxetan) in the treatment of patients with prostate cancer
- Oralair 100 IR & 300 IR, grass pollen allergen extract indicated for the treatment of children (aged 5 years and older), adolescents, and adults (up to 65 years of age) diagnosed with allergic rhinitis with or without conjunctivitis
We encourage you to read the full documents and submit comments within the prescribed period of 7 days from the date of publication.
